An Open Label Phase Ia/b Dose Escalation Followed by Dose Expansion Safety and Tolerability Trial of CAP-100, a Humanized C-C-chemokine Receptor 7 Antibody, Administered as Monotherapy in Subjects With r/r Chronic Lymphocytic Leukemia

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 21 Aug 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CAP 100 (Primary)
Indications Chronic lymphocytic leukaemia
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Catapult Therapeutics

Most Recent Events

19 Aug 2024 Planned number of patients changed from 25 to 18.
14 Feb 2024 Planned End Date changed from 1 Sep 2023 to 1 Apr 2025.
14 Feb 2024 Planned primary completion date changed from 1 Sep 2023 to 1 Jan 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight